{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T04:56:38Z","timestamp":1768798598518,"version":"3.49.0"},"reference-count":96,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2001,9,1]],"date-time":"2001-09-01T00:00:00Z","timestamp":999302400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2001,9,1]],"date-time":"2001-09-01T00:00:00Z","timestamp":999302400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"published-print":{"date-parts":[[2001,9]]},"DOI":"10.1023\/a:1013089924994","type":"journal-article","created":{"date-parts":[[2002,12,23]],"date-time":"2002-12-23T15:49:56Z","timestamp":1040658596000},"page":"7-17","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["New Anticoagulant Drugs"],"prefix":"10.1007","volume":"12","author":[{"given":"Jeffrey I.","family":"Weitz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2001,9,1]]},"reference":[{"key":"359719_CR1","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1056\/NEJM199201303260506","volume":"326","author":"V Fuster","year":"1992","unstructured":"Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 1992;326:310\u2013318.","journal-title":"N Engl J Med"},{"key":"359719_CR2","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1056\/NEJM199203193261205","volume":"326","author":"B Furie","year":"1992","unstructured":"Furie B, Furie BC. Molecular and cellular biology of blood coagulation. N Engl J Med 1992;326:800\u2013806.","journal-title":"N Engl J Med"},{"key":"359719_CR3","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1055\/s-0038-1656125","volume":"77","author":"MM van den Eijnden","year":"1997","unstructured":"van den Eijnden MM, Steenhauer SI, Reitsma PH, Bertina RM. Tissue factor expression during monocyte\u2013macrophage differentiation. Thromb Haemost 1997;77:1129\u20131136.","journal-title":"Thromb Haemost"},{"key":"359719_CR4","doi-asserted-by":"crossref","first-page":"19089","DOI":"10.1016\/S0021-9258(18)41745-0","volume":"267","author":"M Yamamoto","year":"1992","unstructured":"Yamamoto M, Nakagaki T, Kisiel W. Tissue factordependent autoactivation of human blood coagulation factor. J Biol Chem 1992;267:19089\u201319094.","journal-title":"J Biol Chem"},{"key":"359719_CR5","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1055\/s-2007-993291","volume":"19","author":"D Gailani","year":"1993","unstructured":"Gailani D, Broze GJ Jr. Factor XI activation by thrombin and factor XIa. Semin Thromb Hemost 1993;19:396\u2013404.","journal-title":"Semin Thromb Hemost"},{"key":"359719_CR6","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1056\/NEJM199105303242206","volume":"324","author":"H. J. Heparin","year":"1991","unstructured":"Hirsh J. Heparin. N Engl J Med 1991;324:1565\u20131574.","journal-title":"N Engl J Med"},{"key":"359719_CR7","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1056\/NEJM199709043371007","volume":"337","author":"JI Weitz","year":"1997","unstructured":"Weitz JI. Low molecular weight heparins. N Engl J Med 1997;337:688\u2013698.","journal-title":"N Engl J Med"},{"key":"359719_CR8","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1055\/s-0038-1649913","volume":"74","author":"DM Tollefsen","year":"1995","unstructured":"Tollefsen DM. Insight into the mechanism of action of heparin cofactor II. Thromb Haemost 1995;74:1209\u20131214.","journal-title":"Thromb Haemost"},{"key":"359719_CR9","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1023\/A:1012160703533","volume":"14","author":"TM Rivera","year":"1997","unstructured":"Rivera TM, Leone\u2013Bay A, Paton DR, Leipold HR, Baughman RA. Oral delivery of heparin in combination with sodium N\u2013[8\u2013(2\u2013hydroxybenzoyl)amino] caprylate: pharmacological considerations. Pharm Res 1997;14:1830\u20131834.","journal-title":"Pharm Res"},{"key":"359719_CR10","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1055\/s-0037-1614625","volume":"82","author":"V DiCarlo","year":"1999","unstructured":"DiCarlo V, Agnelli G, Prandoni P, et al. Dermatan sulphate for the prevention of postoperative venous thromboembolism in patients with cancer. DOS (Dermatan sulphate in Oncologic Surgery) Study Group. Thromb Haemost 1999;82:30\u201334.","journal-title":"Thromb Haemost"},{"key":"359719_CR11","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/BF02912457","volume":"27","author":"M Miglioli","year":"1997","unstructured":"Miglioli M, Pironi L, Ruggeri E, et al. Bioavailability of Desmin, a low molecular weight dermatan sulphate, after subcutaneous administration to healthy volunteers. Int J Clin Lab Res 1997;27:195\u2013198.","journal-title":"Int J Clin Lab Res"},{"key":"359719_CR12","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1016\/0006-2952(91)90431-4","volume":"42","author":"RJ Linhardt","year":"1991","unstructured":"Linhardt RJ, al\u2013Hakim A, Liu JA, et al. Structural features of dermatan sulfates and their relationship to anticoagulant antithrombotic activities. Biochem Pharmacol 1991;42:1609\u20131619.","journal-title":"Biochem Pharmacol"},{"key":"359719_CR13","doi-asserted-by":"publisher","first-page":"3619","DOI":"10.1073\/pnas.86.10.3619","volume":"86","author":"PJ Hogg","year":"1989","unstructured":"Hogg PJ, Jackson CM. Fibrin monomer protects thrombin from inactivation by heparin\u2013antithrombin III: implications for heparin efficacy. Proc Natl Acad Sci (USA) 1989;86:3619\u20133623.","journal-title":"Proc Natl Acad Sci (USA)"},{"key":"359719_CR14","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1172\/JCI114723","volume":"86","author":"JI Weitz","year":"1990","unstructured":"Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot\u2013bound thrombin is protected from inhibition by heparin\u2013antithrombin III but is susceptible to inactivation by antithrombin III\u2013dependent inhibitors. J Clin Invest 1990;86:385\u2013391.","journal-title":"J Clin Invest"},{"key":"359719_CR15","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1161\/01.CIR.97.6.544","volume":"97","author":"JI Weitz","year":"1998","unstructured":"Weitz JI, Leslie B, Hudoba M. Thrombin binds to soluble fibrin degradation products where it is protected from inhibition by heparin\u2013antithrombin but susceptible to inactivation by antithrombin\u2013independent inhibitors. Circulation 1998;97:544\u2013552.","journal-title":"Circulation"},{"key":"359719_CR16","doi-asserted-by":"crossref","first-page":"3980","DOI":"10.1016\/S0021-9258(17)35610-7","volume":"261","author":"DA Lane","year":"1986","unstructured":"Lane DA, Pejler J, Flynn AM, Thompson EA, Lindahl U. Neutralization of heparin\u2013related saccharides by histidine\u2013rich glycoprotein and platelet factor 4. J Biol Chem 1986;261:3980\u20133986.","journal-title":"J Biol Chem"},{"key":"359719_CR17","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1073\/pnas.83.4.1084","volume":"83","author":"RP Harvey","year":"1986","unstructured":"Harvey RP, Degryse E, Stefani L, et al. Cloning and expression of cDNA coding for the anticoagulant hirudin from blood sucking leech, Hirudo medicinalis. Proc Natl Acad Sci (USA) 1986;83:1084\u20131088.","journal-title":"Proc Natl Acad Sci (USA)"},{"key":"359719_CR18","doi-asserted-by":"publisher","first-page":"4622","DOI":"10.1021\/bi00364a025","volume":"25","author":"SR Stone","year":"1986","unstructured":"Stone SR, Hofsteenge J. Kinetics of inhibition of thrombin by hirudin. Biochemistry 1986;25:4622\u20134628.","journal-title":"Biochemistry"},{"key":"359719_CR19","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1126\/science.2374926","volume":"249","author":"TJ Rydel","year":"1990","unstructured":"Rydel TJ, Ravichandran KG, Tulinsky A, et al. The structure of a complex of recombinant hirudin and human\u2013thrombin. Science 1990;249:277\u2013280.","journal-title":"Science"},{"key":"359719_CR20","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1177\/106002809202601211","volume":"26","author":"KA Stringer","year":"1992","unstructured":"Stringer KA, Lindenfeld J. Hirudins: antithrombin anticoagulants. Ann Pharmacother 1992;26:1535\u20131540.","journal-title":"Ann Pharmacother"},{"key":"359719_CR21","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/ajh.2830500105","volume":"50","author":"F Schiele","year":"1995","unstructured":"Schiele F, Vuillemenot A, Kramarz P, et al. Use of recombinant hirudin as antithrombotic treatment in patients with heparin\u2013induced thrombocytopenia. Am J Hematol 1995;50:25\u201329.","journal-title":"Am J Hematol"},{"key":"359719_CR22","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1002\/ajh.2830430417","volume":"43","author":"S Nand","year":"1993","unstructured":"Nand S. Hirudin therapy for heparin\u2013associated thrombocytopenia and deep venous thrombosis. Am J Hematol 1993;43:310\u2013311.","journal-title":"Am J Hematol"},{"key":"359719_CR23","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/S0022-5223(05)80033-9","volume":"110","author":"FC Riess","year":"1995","unstructured":"Riess FC, Lower C, Seelig C. Recombinant hirudin as a new anticoagulant during cardiac operations instead of heparin: successful for aortic valve replacement in man. J Thorac Cardiovasc Surg 1995;110:265\u2013267.","journal-title":"J Thorac Cardiovasc Surg"},{"key":"359719_CR24","first-page":"A53","volume":";68","author":"B Potzsch","year":"1994","unstructured":"Potzsch B, Iversen S, Riess FC. Recombinant hirudin as an anticoagulant in open\u2013heart surgery; a case report. Ann Hematol 1994;68:A53.","journal-title":"Ann Hematol"},{"key":"359719_CR25","first-page":"26","volume":"35","author":"TL Ortel","year":"1998","unstructured":"Ortel TL, Chong BH. New treatment options for heparin\u2013induced thrombocytopenia. Semin Hematol 1998;35:26\u201334.","journal-title":"Semin Hematol"},{"key":"359719_CR26","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/S0140-6736(96)91200-3","volume":"347","author":"BI Eriksson","year":"1996","unstructured":"Eriksson BI, Ekman S, Kalebo P, Zachrisson B, Bach D, Close P. Prevention of deep\u2013vein thrombosis after total hip replacement: direct thrombin inhibition with recombinant hirudin, CGP 39393. Lancet 1996; 347:635\u2013639.","journal-title":"Lancet"},{"key":"359719_CR27","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1056\/NEJM199711063371901","volume":"337","author":"BI Eriksson","year":"1997","unstructured":"Eriksson BI, Wille\u2013Jorgensen P, Kalebo P, et al. A comparison of recombinant hirudin with a low\u2013molecular\u2013weight heparin to prevent thromboembolic complications after total hip replacement. N Engl J Med 1997;337:1329\u20131335.","journal-title":"N Engl J Med"},{"key":"359719_CR28","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1161\/01.CIR.96.3.769","volume":"96","author":"OASIS Investigators.","year":"1997","unstructured":"OASIS Investigators. Comparison of the effects of two doses of recombinant hirudin compared with heparin in patients with acute myocardial ischemia without ST elevation: a pilot study. Circulation 1997;96:769\u2013777.","journal-title":"Circulation"},{"key":"359719_CR29","first-page":"429","volume":"353","author":"The OASIS\u20132 Investigators.","year":"1998","unstructured":"The OASIS\u20132 Investigators. Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularization procedures in patients with acute myocardial ischemia without ST elevation: a randomized trial. Lancet 1998;353:429\u2013448.","journal-title":"Lancet"},{"key":"359719_CR30","doi-asserted-by":"publisher","first-page":"7095","DOI":"10.1021\/bi00482a021","volume":"29","author":"JM Maraganore","year":"1990","unstructured":"Maraganore JM, Bourdon P, Jablonski J, Ramachandran KL, Fenton JW. Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors or thrombin. Biochemistry 1990;29:7095\u20137101.","journal-title":"Biochemistry"},{"key":"359719_CR31","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1042\/bj2830737","volume":"283","author":"JI Witting","year":"1992","unstructured":"Witting JI, Bourdon P, Brezniak DV, Maraganore JM, Fenton JW. Thrombin\u2013specific inhibition by and slow cleavage of hirulog\u20131. Biochem J 1992;283:737\u2013743.","journal-title":"Biochem J"},{"key":"359719_CR32","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1056\/NEJM199509213331204","volume":"333","author":"JA Bittl","year":"1995","unstructured":"Bittl JA, Strony J, Brinker JA, et al. Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog Angioplasty Study Investigators. N Engl J Med 1995;333:764\u2013769.","journal-title":"N Engl J Med"},{"key":"359719_CR33","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S0002-9149(98)00766-8","volume":"82","author":"JA Bittl","year":"1998","unstructured":"Bittl JA, Feit F. A randomized comparison of bivalirudin and heparin in patients undergoing coronary angioplasty for postinfarction angina. Hirulog Angioplasty Study Investigators. Am J Cardiol 1998;82: 43\u201349.","journal-title":"Am J Cardiol"},{"key":"359719_CR34","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1055\/s-0038-1651573","volume":"69","author":"I Fox","year":"1993","unstructured":"Fox I, Dawson A, Loynds P, et al. Anticoagulant activity of hirulog, a direct thrombin inhibitor, in humans. Thromb Haemost 1993;69:157\u2013163.","journal-title":"Thromb Haemost"},{"key":"359719_CR35","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1097\/00019501-199606000-00008","volume":"7","author":"D Fitzgerald","year":"1996","unstructured":"Fitzgerald D, Murphy N. Argatroban: a synthetic thrombin inhibitor of low relative molecular mass. Coronary Artery Disease 1996;7:455\u2013458.","journal-title":"Coronary Artery Disease"},{"key":"359719_CR36","first-page":"26a","volume":"94","author":"UG Eriksson","year":"1999","unstructured":"Eriksson UG, Johansson L, Frison L, et al. Single and repeated oral dosing of H376\/95, a prodrug of the direct thrombin inhibitor melagatran, to young healthy male subjects. Blood 1999;94:26a (Abstract #101).","journal-title":"Blood"},{"key":"359719_CR37","first-page":"26a","volume":"94","author":"D Gustafsson","year":"1999","unstructured":"Gustafsson D, Nystrom J\u2013E, Carlsson S, et al. Pharmacodynamic properties of H376\/95, a prodrug of the direct thrombin inhibitor melagatran, intended for oral use. Blood 1999;94:26a (Abstract #102).","journal-title":"Blood"},{"key":"359719_CR38","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1172\/JCI115495","volume":"88","author":"CR Benedict","year":"1991","unstructured":"Benedict CR, Ryan J, Wolitzky B, et al. Active siteblocked factor IXa prevents intravascular thrombus formation in the coronary vasculature without inhibiting extravascular coagulation in a canine thrombosis model. J Clin Invest 1991;88:1760\u20131765.","journal-title":"J Clin Invest"},{"key":"359719_CR39","doi-asserted-by":"crossref","first-page":"11574","DOI":"10.1016\/S0021-9258(17)39070-1","volume":"260","author":"SP Bajaj","year":"1985","unstructured":"Bajaj SP, Rapaport SI, Maki SL. A monoclonal antibody to factor IX that inhibits the factor VIII: Ca potentiation of factor X activation. J Biol Chem 1985; 260:11574\u201311580.","journal-title":"J Biol Chem"},{"key":"359719_CR40","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1055\/s-0037-1614852","volume":"82","author":"GZ Feuerstein","year":"1999","unstructured":"Feuerstein GZ, Toomey JR, Valocik R, Koster P, Patel A, Blackburn MN. An inhibitory anti\u2013factor IX antibody effectively reduces thrombus formation in a rat model of venous thrombosis. Thromb Haemost 1999; 82:1443\u20131450.","journal-title":"Thromb Haemost"},{"key":"359719_CR41","doi-asserted-by":"publisher","first-page":"2554","DOI":"10.1161\/01.ATV.19.10.2554","volume":"19","author":"GZ Feuerstein","year":"1999","unstructured":"Feuerstein GZ, Patel A, Toomey JR, et al. Antithrombotic efficacy of a novel murine antihuman factor IX antibody in rats. Arterioscler Thromb Vasc Biol 1999; 19:2554\u20132562.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"359719_CR42","doi-asserted-by":"crossref","first-page":"4197","DOI":"10.1182\/blood.V91.11.4197","volume":"91","author":"JM Herbert","year":"1998","unstructured":"Herbert JM, Herault JP, Bernat A, et al. Biochemical and pharmacological properties of SANORG 340006, a New Anticoagulant Drugs 15 potent and long\u2013acting synthetic pentasaccharide. Blood 1998;91;4197\u20134205.","journal-title":"Blood"},{"key":"359719_CR43","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1056\/NEJM200103013440901","volume":"344","author":"AG Turpie","year":"2001","unstructured":"Turpie AG, Gallus AS, Hoek JA, et al. A synthetic pentasaccharide for the prevention of deep\u2013vein thrombosis after total hip replacement. N Engl J Med 2001;344:619\u2013625.","journal-title":"N Engl J Med"},{"key":"359719_CR44","first-page":"490a","volume":"96","author":"MR Lassen","year":"2000","unstructured":"Lassen MR. The Ephesus Study: comparison of the first synthetic factor Xa inhibitor with low molecular weight heparin (LMWH) in the prevention of venous thromboembolism (VTE) after elective hip replacement surgery (abstract). Blood 2000;96:490a (Abstract #2109).","journal-title":"Blood"},{"key":"359719_CR45","first-page":"490a","volume":"96","author":"B Eriksson","year":"2000","unstructured":"Eriksson B. The Penthifra Study: comparison of the first synthetic factor Xa inhibitor with low molecular weight heparin (LMWH) in the prevention of venous thromboembolism (VTE) after hip fracture surgery (abstract). Blood 2000;96:490a (Abstract #2110).","journal-title":"Blood"},{"key":"359719_CR46","doi-asserted-by":"crossref","first-page":"490a","DOI":"10.1182\/blood.V96.13.4236","volume":"96","author":"K Bauer","year":"2000","unstructured":"Bauer K. The Pentamaks Study: comparison of the first synthetic factor Xa inhibitor with low molecular weight heparin in the prevention of venous thromboembolism (VTE) after elective major knee surgery (abstract). Blood 2000;96:490a (Abstract #2111).","journal-title":"Blood"},{"key":"359719_CR47","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1055\/s-0038-1646193","volume":"70","author":"GP Vlasuk","year":"1993","unstructured":"Vlasuk GP. Structural and functional characterization of tick anticoagulant peptide (TAP): a potent and selective inhibitor of blood coagulation factor Xa. Thromb Haemost 1993;70:212\u2013216.","journal-title":"Thromb Haemost"},{"key":"359719_CR48","doi-asserted-by":"crossref","first-page":"9718","DOI":"10.1016\/S0021-9258(18)47993-8","volume":"262","author":"G Tuszyuski","year":"1987","unstructured":"Tuszyuski G, Gasic TB, Gasic GJ. Isolation and characterization of antistasin. J Biol Chem 1987;262:9718\u20139723.","journal-title":"J Biol Chem"},{"key":"359719_CR49","doi-asserted-by":"crossref","first-page":"16694","DOI":"10.1016\/S0021-9258(19)84761-0","volume":"264","author":"C Dunwiddie","year":"1989","unstructured":"Dunwiddie C, Thornberry NA, Bull HG, et al. Antistasin: a leech\u2013derived inhibitor of factor Xa: kinetic analysis of enzyme inhibition and identification of the reactive site. J Biol Chem 1989;264:16694\u201316699.","journal-title":"J Biol Chem"},{"key":"359719_CR50","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1055\/s-0037-1614857","volume":"82","author":"F Faria","year":"1999","unstructured":"Faria F, Kelen EM, Sampaio CA, Bon C, Duval N, Chudzinski\u2013Tavassi AM. A new factor Xa inhibitor (lefaxin) from the Haementeria depressa leech. Thromb Haemost 1999;82:1469\u20131473.","journal-title":"Thromb Haemost"},{"key":"359719_CR51","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/S0022-3565(25)12377-X","volume":"276","author":"JM Herbert","year":"1996","unstructured":"Herbert JM, Bernat A, Dol F, Herault JP, Crepon B, Lormeau JC. DX\u20139065a, a novel, synthetic, selective and orally active inhibitor of factor Xa: in vitro and in vivo studies. J Pharmacol Exper Ther 1996;276:1030\u20131038.","journal-title":"J Pharmacol Exper Ther"},{"key":"359719_CR52","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1055\/s-0037-1614941","volume":"79","author":"Y Taniuchi","year":"1998","unstructured":"Taniuchi Y, Sakai Y, Hisamichi N, et al. Biochemical and pharmacological characterization of YM\u201360828, a newly synthesized and orally active inhibitor of human factor Xa. Thromb Haemost 1998;79:543\u2013548.","journal-title":"Thromb Haemost"},{"key":"359719_CR53","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0022-3565(24)35299-1","volume":"292","author":"PC Wong","year":"2000","unstructured":"Wong PC, Quan ML, Crain EJ, Watson CA, Wexler RR, Knabb RM. Nonpeptide factor Xa inhibitors: I. Studies with SF303 and SK549, a new antithrombotic. J Pharmacol Exp Ther 2000;292:351\u2013357.","journal-title":"J Pharmacol Exp Ther"},{"key":"359719_CR54","doi-asserted-by":"publisher","first-page":"2760","DOI":"10.1021\/jm980406a","volume":"42","author":"ML Quan","year":"1999","unstructured":"Quan ML, Ellis CD, Liauw AY, et al. Design and synthesis of isoxazoline derivatives as factor Xa inhibitors. J Med Chem 1999;42:2760\u20132773.","journal-title":"J Med Chem"},{"key":"359719_CR55","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1055\/s-0038-1642658","volume":"74","author":"GJ Broze Jr","year":"1995","unstructured":"Broze GJ Jr. Tissue factor pathway inhibitor. Thromb Haemost 1995;74:90\u201393.","journal-title":"Thromb Haemost"},{"key":"359719_CR56","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1073\/pnas.93.5.2149","volume":"93","author":"P Stassens","year":"1996","unstructured":"Stassens P, Bergum PW, Gansemans Y, et al. Anticoagulant repertoire of the hookworm Ancylostoma caninum. Proc Natl Acad Sci USA 1996;93:2149\u20132154.","journal-title":"Proc Natl Acad Sci USA"},{"key":"359719_CR57","doi-asserted-by":"publisher","first-page":"6152","DOI":"10.1073\/pnas.92.13.6152","volume":"92","author":"M Cappello","year":"1995","unstructured":"Cappello M, Vlasuk GP, Bergum PW, Huang S, Hotez PJ. Ancylostoma caninum anticoagulant peptide: a hookworm\u2013derived inhibitor of human coagulation factor Xa. Proc Natl Acad Sci USA 1995;92:6152\u20136156.","journal-title":"Proc Natl Acad Sci USA"},{"key":"359719_CR58","doi-asserted-by":"crossref","first-page":"491a","DOI":"10.1182\/blood.V96.2.491.014k28_491_497","volume":"96","author":"A Lee","year":"2000","unstructured":"Lee A, Agnelli G, Buller H, et al. A dose\u2013response study of the factor VIIa\/tissue factor inhibitor rNAPc2 in the prevention of postoperative venous thrombosis in patients undergoing total knee arthroplasty (abstract). Blood 2000;96:491a (#2114).","journal-title":"Blood"},{"key":"359719_CR59","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1055\/s-0038-1657503","volume":"78","author":"CT Esmon","year":"1997","unstructured":"Esmon CT, Ding W, Yasuhiro K, et al. The protein C pathway: new insights. Thromb Haemost 1997;78: 70\u201374.","journal-title":"Thromb Haemost"},{"key":"359719_CR60","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJM200103083441001","volume":"344","author":"GR Bernard","year":"2001","unstructured":"Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699\u2013709.","journal-title":"N Engl J Med"},{"key":"359719_CR61","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1055\/s-0038-1657558","volume":"78","author":"JE Sadler","year":"1997","unstructured":"Sadler JE. Thrombomodulin structure and function. Thromb Haemost 1997;78:392\u2013395.","journal-title":"Thromb Haemost"},{"key":"359719_CR62","doi-asserted-by":"crossref","first-page":"12602","DOI":"10.1016\/S0021-9258(19)38386-3","volume":"265","author":"JF Parkinson","year":"1990","unstructured":"Parkinson JF, Grinnell BW, Moore RE, Hoskins J, Vlahos CJ, Bang NU. Stable expression of a secretable deletion mutation of recombinant human thrombomodulin in mammalian cells. J Biol Chem 1990; 265:12602\u201312610.","journal-title":"J Biol Chem"},{"key":"359719_CR63","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1182\/blood.V75.7.1396.1396","volume":"75","author":"K Gomi","year":"1990","unstructured":"Gomi K, Zushi M, Honda G, et al. Antithrombotic effect of recombinant human thrombomodulin on thrombin\u2013induced thromboembolism in mice. Blood 1990;75:1369\u20131399.","journal-title":"Blood"},{"key":"359719_CR64","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1055\/s-0038-1642459","volume":"71","author":"Y Aoki","year":"1994","unstructured":"Aoki Y, Ohishi R, Takei R, et al. Effects of recombinant human soluble thrombomodulin (rhs\u2013TM) on a rat model of disseminated intravascular coagulation with decreased levels of plasma antithrombin III. Thromb Haemost 1994;71:452\u2013455.","journal-title":"Thromb Haemost"},{"key":"359719_CR65","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/378413a0","volume":"378","author":"CS Gibbs","year":"1995","unstructured":"Gibbs CS, Coutre SE, Tsiang M, et al. Conversion of thrombin into an anticoagulant by protein engineering. Nature 1995;378:413\u2013416.","journal-title":"Nature"},{"key":"359719_CR66","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1055\/s-0038-1657592","volume":"78","author":"LLK Leung","year":"1997","unstructured":"Leung LLK, Gibbs CS. Modulation of thrombin's procoagulant and anticoagulant properties. Thromb Haemost 1997;78:577\u2013580.","journal-title":"Thromb Haemost"},{"key":"359719_CR67","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1126\/science.273.5280.1389","volume":"273","author":"DT Berg","year":"1996","unstructured":"Berg DT, Wiley MR, Grinnell BW. Enhanced protein C activation and inhibition of fibrinogen cleavage by a thrombin modulator. Science 1996;273:1389\u20131391.","journal-title":"Science"},{"key":"359719_CR68","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1055\/s-0038-1649642","volume":"70","author":"S Fujii","year":"1993","unstructured":"Fujii S, Sawa H, Sobel BE. Inhibition of endothelial cell expression of plasminogen activator inhibitor type\u20131 by gemfibrozil. Thromb Haemost 1993;70:642\u2013647.","journal-title":"Thromb Haemost"},{"key":"359719_CR69","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1161\/01.CIR.92.4.767","volume":"92","author":"SL Brown","year":"1995","unstructured":"Brown SL, Sobel BE, Fujii S. Attenuation of the synthesis of plasminogen activator inhibitor type 1 by niacin: a potential link between lipid lowering and fibrinolysis. Circulation 1995;92:767\u2013772.","journal-title":"Circulation"},{"key":"359719_CR70","doi-asserted-by":"publisher","first-page":"27942","DOI":"10.1074\/jbc.270.46.27942","volume":"270","author":"J Kvassman","year":"1995","unstructured":"Kvassman J, Lawrence D, Shore J. The acid stabilization of plasminogen activator inhibitor\u20131 depends on protonation of a single group that affects loop insertion into sheet A. J Biol Chem 1995;270:27942\u201327947.","journal-title":"J Biol Chem"},{"key":"359719_CR71","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1172\/JCI117937","volume":"95","author":"DT Eitzman","year":"1995","unstructured":"Eitzman DT, Fay WP, Lawrence DA, et al. Peptidemediated inactivation of recombinant and platelet plasminogen activator inhibitor\u20131 in vitro. J Clin Invest 1995;95:2416\u20132420.","journal-title":"J Clin Invest"},{"key":"359719_CR72","first-page":"916","volume":"96","author":"P Friederich","year":"1997","unstructured":"Friederich P, Levi M, Biemond B, et al. Novel low\u2013molecular\u2013weight inhibitor of PAI\u20131 (XR5118) promotes endogenous fibrinolysis and reduces postthrombolysis thrombus growth in rabbits. Circulation 1997;96:916\u2013921.","journal-title":"Circulation"},{"key":"359719_CR73","doi-asserted-by":"publisher","first-page":"16603","DOI":"10.1074\/jbc.271.28.16603","volume":"271","author":"L Bajzar","year":"1996","unstructured":"Bajzar L, Morser J, Nesheim M. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin\u2013thrombomodulin complex. J Biol Chem 1996;271:16603\u201316608.","journal-title":"J Biol Chem"},{"key":"359719_CR74","doi-asserted-by":"publisher","first-page":"14477","DOI":"10.1074\/jbc.272.22.14477","volume":"272","author":"DV Sakharov","year":"1997","unstructured":"Sakharov DV, Plow EF, Rijken DC. On the mechanism of the antifibrinolytic activity of plasma carboxypeptidase B. J Biol Chem 1997;272:14477\u201314482.","journal-title":"J Biol Chem"},{"key":"359719_CR75","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1161\/01.CIR.93.7.1328","volume":"93","author":"A Redlitz","year":"1996","unstructured":"Redlitz A, Nicolini FA, Malycky JL, Topol EJ, Plow EF. Inducible carboxypeptidase activity: a role in clot lysis in vivo. Circulation 1996;93:1328\u20131330.","journal-title":"Circulation"},{"key":"359719_CR76","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1182\/blood.V94.8.2735.420k30_2735_2743","volume":"94","author":"P Klement","year":"1999","unstructured":"Klement P, Liao P, Bajzar L. A novel approach to arterial thrombolysis. Blood 1999;94:2735\u20132743.","journal-title":"Blood"},{"key":"359719_CR77","doi-asserted-by":"publisher","first-page":"25510","DOI":"10.1074\/jbc.274.36.25510","volume":"274","author":"SW Hall","year":"1999","unstructured":"Hall SW, Nagashima M, Zhao L, Morser J, Leung LL. Thrombin interacts with thrombomodulin, protein C, and thrombin\u2013activatable fibrinolysis inhibitor via specific and distinct domains. J Biol Chem 1999; 274:25510\u201325516.","journal-title":"J Biol Chem"},{"key":"359719_CR78","first-page":"177","volume":"29","author":"MW Mosesson","year":"1992","unstructured":"Mosesson MW. The roles of fibrinogen and fibrin in hemostasis and thrombosis. Semin Hematol 1992; 29:177\u2013178.","journal-title":"Semin Hematol"},{"key":"359719_CR79","doi-asserted-by":"publisher","first-page":"357","DOI":"10.3109\/10408369609084691","volume":"33","author":"L Muszbek","year":"1996","unstructured":"Muszbek L, Adany R, Mikkola H. Novel aspects of blood coagulation factor XIII. I. Structure, distribution, activation, and function. Crit Rev Clin Lab Sci 1996;33:357\u2013421.","journal-title":"Crit Rev Clin Lab Sci"},{"key":"359719_CR80","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1055\/s-0038-1656085","volume":"77","author":"L Seale","year":"1997","unstructured":"Seale L, Finney S, Sawyer RT, Wallis RB. Tridegin, a novel peptidic inhibitor of factor XIIIa from the leech, Haementeria ghilianii, enhances fibrinolysis in vitro. Thromb Haemost 1997;77:959\u2013963.","journal-title":"Thromb Haemost"},{"key":"359719_CR81","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1042\/bj3240797","volume":"324","author":"S Finney","year":"1997","unstructured":"Finney S, Seale L, Sawyer RT, Wallis RB. Tridegin, a new peptidic inhibitor of factor XIIIa, from the bloodsucking leech Haementeria ghilianii. Biochem J 1997; 324:797\u2013805.","journal-title":"Biochem J"},{"key":"359719_CR82","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1097\/00001721-199102000-00025","volume":"2","author":"IP Baskova","year":"1991","unstructured":"Baskova IP, Nikonov GI. Destabilase, the novel epsilon\u2013( gamma\u2013Glu)\u2013Lys isopeptidase with thrombolytic activity. Blood Coagul Fibrinol 1991;2:167\u2013172.","journal-title":"Blood Coagul Fibrinol"},{"key":"359719_CR83","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s004380050291","volume":"253","author":"L Zavalova","year":"1996","unstructured":"Zavalova L, Lukyanov S, Baskova I, et al. Genes from the medicinal leech (Hirudo medicinalis) coding for unusual enzymes that specifically cleave endo\u2013epsilon (gamma\u2013Glu)\u2013Lys isopeptide bonds and help to dissolve blood clots. Mol Gen Genet 1996;253:20\u201325.","journal-title":"Mol Gen Genet"},{"key":"359719_CR84","first-page":"28","volume":"348","author":"A Planes","year":"1996","unstructured":"Planes A, Vochelle N, Darmon J\u2013Y, Fagola M, Bellaud M, Huet Y. Risk of deep venous thrombosis after hospital discharge in patients having undergone total hip replacement: double\u2013blind randomized comparison of enoxaparin and placebo. Lancet 1996;348:28\u201331.","journal-title":"Lancet"},{"key":"359719_CR85","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1056\/NEJM199609053351002","volume":"335","author":"D Bergqvist","year":"1996","unstructured":"Bergqvist D, Benoni G, Bjurgell O, et al. Low\u2013molecular\u2013weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. N Engl J Med 1996;335:696\u2013700.","journal-title":"N Engl J Med"},{"key":"359719_CR86","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1055\/s-0038-1655901","volume":"77","author":"OE Dahl","year":"1997","unstructured":"Dahl OE, Andreassen G, Aspelin T, et al. Prolonged thromboprophylaxis following hip replacement surgery\u2013results of a double\u2013blind, prospective, randomized, placebo\u2013controlled study with dalteparin (Fragmin). Thromb Haemost 1997;77:26\u201331.","journal-title":"Thromb Haemost"},{"key":"359719_CR87","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1161\/01.CIR.98.16.1610","volume":"98","author":"RA Baughman","year":"1998","unstructured":"Baughman RA, Kapoor SC, Agarwal RK, et al. Oral delivery of anticoagulant doses of heparin. A randomized, double\u2013blind controlled study in humans. Circulation 1998;98:1610\u20131615.","journal-title":"Circulation"},{"key":"359719_CR88","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/S0002-9610(98)00127-5","volume":"176","author":"MD Gonze","year":"1998","unstructured":"Gonze MD, Manord JD, Leone\u2013Bay A, et al. Orally administered heparin for preventing deep venous thrombosis. Am J Surg 1998;176:176\u2013178.","journal-title":"Am J Surg"},{"key":"359719_CR89","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1055\/s-0038-1649783","volume":"74","author":"MN Levine","year":"1995","unstructured":"Levine MN, Hirsh J, Gent M, et al. Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis. Thromb Haemost 1995;74:606\u2013611.","journal-title":"Thromb Haemost"},{"key":"359719_CR90","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1056\/NEJM199506223322501","volume":"332","author":"S Schulman","year":"1995","unstructured":"Schulman S, Rhedin A\u2013S, Lindmarker P, et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. N Engl J Med 1995;332:1661\u20131665.","journal-title":"N Engl J Med"},{"key":"359719_CR91","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7326\/0003-4819-125-1-199607010-00001","volume":"125","author":"P Prandoni","year":"1996","unstructured":"Prandoni P, Lensing AWA, Cogo A, et al. The longterm clinical course of acute deep venous thrombosis. Ann Intern Med 1996;125:1\u20137.","journal-title":"Ann Intern Med"},{"key":"359719_CR92","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1056\/NEJM199903253401201","volume":"340","author":"C Kearon","year":"1999","unstructured":"Kearon C, Gent M, Hirsh J, et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 1999;340: 901\u2013907.","journal-title":"N Engl J Med"},{"key":"359719_CR93","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1161\/01.CIR.94.5.911","volume":"94","author":"Antman EM for the TIMI 9B Investigators.","year":"1996","unstructured":"Antman EM for the TIMI 9B Investigators. Hirudin in acute myocardial infarction: thrombolysis and thrombin inhibition in myocardial infarction (TIMI) 9B trial. Circulation 1996;94:911\u2013921.","journal-title":"Circulation"},{"key":"359719_CR94","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1056\/NEJM199609123351103","volume":"335","author":"GUSTO IIb Investigators.","year":"1996","unstructured":"GUSTO IIb Investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med 1996;335:775\u2013782.","journal-title":"N Engl J Med"},{"key":"359719_CR95","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1016\/S0735-1097(98)00138-7","volume":"31","author":"BK Metz","year":"1998","unstructured":"Metz BK, White HD, Granger CB, et al. Randomized comparison of direct thrombin inhibition versus heparin in conjunction with fibrinolytic therapy for acute myocardial infarction: results from the GUSTO IIb trial. J Am Coll Cardiol 1998;31:1493\u20131498.","journal-title":"J Am Coll Cardiol"},{"key":"359719_CR96","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1161\/01.CIR.96.7.2155","volume":"96","author":"HD White","year":"1997","unstructured":"White HD, Aylward PE, Frey MJ, et al. Randomized, double\u2013blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Circulation 1997;96:2155\u20132161.","journal-title":"Circulation"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/A:1013089924994.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1023\/A:1013089924994\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/A:1013089924994.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T07:11:26Z","timestamp":1754637086000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1023\/A:1013089924994"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,9]]},"references-count":96,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2001,9]]}},"alternative-id":["359719"],"URL":"https:\/\/doi.org\/10.1023\/a:1013089924994","relation":{},"ISSN":["0929-5305","1573-742X"],"issn-type":[{"value":"0929-5305","type":"print"},{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,9]]},"assertion":[{"value":"1 September 2001","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}